摘要
目的探讨和血明目片治疗外伤性Ⅰ级、Ⅱ级前房积血的临床效果。方法选取2017年1月至2020年7月江西医学高等专科学校第一附属医院收治的外伤性Ⅰ级、Ⅱ级前房积血患者46例(46眼)作为研究对象。按照随机数字表法将其分为对照组(23例)和治疗组(23例)。对照组给予降眼压、局部点眼抗感染等对症处理,治疗组在对照组的基础上给予和血明目片治疗。比较两组治疗后前房积血的吸收时间、治疗前后视力情况以及治疗效果。结果治疗组前房积血的吸收时间短于对照组,差异有统计学意义(P<0.05)。治疗前,对照组视力与治疗组比较,差异无统计学意义(P>0.05);治疗后,两组视力均高于本组治疗前,且治疗组高于对照组,差异有统计学意义(P<0.05)。治疗后,治疗组的治疗效果优于对照组,差异有统计学意义(P<0.05)。结论和血明目片治疗外伤性前房积血,能加快积血吸收时间,及早提高患者视力,疗效显著。
Objective To investigate the clinical effect of Hexue Mingmu Tablet in the treatment of traumatic gradeⅠandⅡhyphema.Methods From January 2017 to July 2020,46 patients(46 eyes)with traumatic gradeⅠandⅡhyphema in the First Affiliated Hospital of Jiangxi Medical College were selected as the research objects.They were divided into control group(23 cases)and treatment group(23 cases)according to random number table method.The control group was treated with reducing intraocular pressure and topical anti infection,while the treatment group was treated with Hexue Mingmu Tablet on the basis of the control group.The absorption time of hyphema,visual acuity before and after treatment and therapeutic effect were compared between the two groups.Results The absorption time of anterior chamber hemorrhage in the treatment group was shorter than that in the control group,and the difference was statistically significant(P<0.05).Before treatment,the visual acuity between the control group and the treatment group was not statistically significant(P>0.05).After treatment,the visual acuity of the two groups was higher than that before the treatment,and the visual acuity of treatment group was higher than that of the control group,the differences were statistically significant(P<0.05).After treatment,the treatment effect of the treatment group was better than that of the control group,and the difference was statistically significant(P<0.05).Conclusion Hexue Mingmu Tablet in the treatment of traumatic hyphema can accelerate the absorption time of hyphema and improve the visual acuity of patients as soon as possible.
作者
李珣旖
何良飞
毛羽佳
LI Xunyi;HE Liangfei;MAO Yujia(Department of Ophthalmology,the First Affiliated Hospital of Jiangxi Medical College,Jiangxi Province,Shangrao334000,China)
出处
《中国当代医药》
CAS
2021年第36期123-125,共3页
China Modern Medicine
基金
江西省卫生计生委科技计划项目(20197551)。